Bon ben oublions le controle agressif du glucose...
 
Alain

  _____  

From: [email protected] [mailto:[email protected]] On Behalf Of Équipe
éditoriale de amc.ca
Sent: 8 mai 2009 04:00
To: [email protected]
Subject: InfoPOEM: Strict blood sugar control increases ICU mortality
(NICE-SUGAR)


Pour assurer la livraison de ce courriel dans votre boîte de réception,
veuillez ajouter [email protected] <mailto:[email protected]>  à votre carnet de
contacts.       

  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/French/Header.jpg>





Strict blood sugar control increases ICU mortality (NICE-SUGAR)

Clinical question 
Does strict blood sugar control improve clinical outcomes in patients
admitted to the intensive care unit?

Bottom line 
This study should provide the final nail in the coffin for the seductive but
ultimately incorrect idea that tight control improves outcomes in intensive
care unit (ICU) patients. In this large, well-designed study, a target of 80
mg/dL to 108 mg/dL (4.5 - 6.0 mmol) actually increased mortality compared
with a target of less than or equal to 180 mg/dL (<= 10 mmol/L), with a
number needed to treat to harm of 38. (LOE =
<http://mailer.cma.ca/t/4157737/234493/102001/0/> 1b)

Reference 
The NICE-SUGAR Study Investigators;
<http://mailer.cma.ca/t/4157737/234493/5230892/0/> Finfer S, Chittock DR, Su
SY, et al. Intensive versus conventional glucose control in critically ill
patients. N Engl J Med 2009;360(13):1283-1297. 

Study design 
Randomized controlled trial (nonblinded)

Funding
Government

Allocation
Concealed 

Setting
Inpatient (ICU only) 


  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/Bullet.gif>
Obtenez  <http://mailer.cma.ca/t/4157737/234493/5231370/0/> des crédits 
 Mainpro        
  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/Bullet.gif>
Discutez  <http://mailer.cma.ca/t/4157737/234493/5230894/0/> de cet
 InfoPOEM       
  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/Bullet.gif>
Archives <http://mailer.cma.ca/t/4157737/234493/145011/0/>      
  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/Bullet.gif>
Bilan  <http://mailer.cma.ca/t/4157737/234493/177011/0/> des crédits    
  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/Bullet.gif>
Plus  <http://mailer.cma.ca/t/4157737/234493/3021/0/> de FMC / DPC      


 <http://mailer.cma.ca/t/4157737/234493/45002/0/> 
Publicité 


  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/Book.gif>
Bibliothécaire  <http://mailer.cma.ca/t/4157737/234493/147004/0/> de l'AMC


  <http://www.cma.ca/multimedia/CMA/NewsLetters/InfoPOEMs/Envelop.gif>
Envoyez-nous vos  <mailto:[email protected]> commentaires 

Synopsis 
A previous study of 524 patients (Crit Care Med 2008;36(12):3190-3197; POEM
#110351) and a previous meta-analysis (JAMA 2008;300(8):933-944; POEM
#101024) failed to show any benefit of tight glucose control for patients
admitted to the ICU. In this large multicenter study, patients expected to
require at least 3 days of ICU treatment were randomly assigned to tight
control with a blood sugar target of 81 mg/dL to 108 mg/dL (4.5 - 6.0
mmol/L) or usual care with a target of 180 mg/dL or less (10 mmol or less).
Analysis was by intention to treat, and groups were balanced at the start of
the study. The mean age of the 6104 participants was 60 years, 36% were
women, and 37% were admitted for an operative reason. The assigned treatment
was discontinued prematurely in 10% of patients in the intensive therapy
group and 7.4% in the usual care group; the most common reason was a change
to palliative care as the goal of treatment. At 90 days, mortality was
higher in the intensive control group (27.5% vs 24.9%; P = .02; number
needed to treat to harm = 38). There was no difference between groups in
length of stay in the ICU. Cardiovascular deaths were more common in the
intensive control group.

Discutez de  <http://mailer.cma.ca/t/4157737/234493/5230894/0/> cet InfoPOEM



Archives

InfoPOEMs  <http://mailer.cma.ca/t/4157737/234493/145011/0/> (contenu
anglais) | CLIPs  <http://mailer.cma.ca/t/4157737/234493/322001/0/> (contenu
anglais) | Critique  <http://mailer.cma.ca/t/4157737/234493/177003/0/> et
pratique

Ressources cliniques

Accueil <http://mailer.cma.ca/t/4157737/234493/94016/0/>  | Manuels
<http://mailer.cma.ca/t/4157737/234493/177004/0/> * | Revues
<http://mailer.cma.ca/t/4157737/234493/177005/0/> * | Information
<http://mailer.cma.ca/t/4157737/234493/145012/0/> médicaments * | Tests
<http://mailer.cma.ca/t/4157737/234493/128015/0/> de laboratoire * |
InfoPOEMs <http://mailer.cma.ca/t/4157737/234493/145011/0/>  | Guide
<http://mailer.cma.ca/t/4157737/234493/324016/0/> de pratique clinique | 

Documents  <http://mailer.cma.ca/t/4157737/234493/177007/0/> d'information
pour les patients * | Bibliothécaire
<http://mailer.cma.ca/t/4157737/234493/147004/0/> de l'AMC *

Raccourcis

MD  <http://mailer.cma.ca/t/4157737/234493/145015/0/> Consult * | STAT!Ref
<http://mailer.cma.ca/t/4157737/234493/148015/0/> * | [email protected]
<http://mailer.cma.ca/t/4157737/234493/177008/0/> * | OVID
<http://mailer.cma.ca/t/4157737/234493/145016/0/> Medline * | Revues
<http://mailer.cma.ca/t/4157737/234493/145014/0/> EBSCO * | JAMC
<http://mailer.cma.ca/t/4157737/234493/177009/0/>  | Essential
<http://mailer.cma.ca/t/4157737/234493/138018/0/> Evidence Plus | MedCalc
<http://mailer.cma.ca/t/4157737/234493/177010/0/> 3000 *

FMC / DPC

Voir les  <http://mailer.cma.ca/t/4157737/234493/3021/0/> cours en ligne |
Bilan  <http://mailer.cma.ca/t/4157737/234493/177011/0/> des crédits

Gestion de la pratique

Accueil <http://mailer.cma.ca/t/4157737/234493/77020/0/>  | Créez un
<http://mailer.cma.ca/t/4157737/234493/140/0/> site Web de pratique |
Clinique  <http://mailer.cma.ca/t/4157737/234493/234014/0/> informatisée |
Bureau <http://mailer.cma.ca/t/4157737/234493/234015/0/>  | Dotation
<http://mailer.cma.ca/t/4157737/234493/234016/0/> en personnel | Finances
<http://mailer.cma.ca/t/4157737/234493/234017/0/>  | Juridique
<http://mailer.cma.ca/t/4157737/234493/234018/0/> et vie privée

* Service aux membres AMC

POEMs veut dire "Patient-Oriented Evidence that Matters". 


Désirez-vous changer le format de vos courriels d'InfoPOEMs quotidiens ou
votre adresse courriel de la liste d'InfoPOEMs quotidiens? 
Gérez vos options  <http://mailer.cma.ca/t/4157737/234493/3026/0/>
d'InfoPOEMs quotidiens à partir du site Web amc.ca. 
Cliquez ici pour vous désabonner
<http://mailer.cma.ca/u?id=234493.2ee32010d4b1d8089bbf2b767ebd5713&o=4157737
&u=http://www.cma.ca/index.cfm/ci_id/324/la_id/2.htm&w=F&a=T&c=F&l=poem> . 


Copyright © 1995-2009 InfoPOEM, Inc. www.infopoems.com
<http://mailer.cma.ca/t/4157737/234493/3966545/0/> . Tous droits réservés. 
Copyright © 2009 Association Médicale Canadienne, Tous droits réservés. 

  <http://mailer.cma.ca/do/4157737/234493/1.gif> 

Répondre à